JPRN-jRCTs071230020
Not yet recruiting
未知
The Impact of Empagliflozin on Left Ventricular Myocardial Stiffness in Heart Failure with Preserved Ejection Fraction - EMPA PV-loop study
Hieda Michinari0 sites38 target enrollmentJune 12, 2023
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Patients with heart failure with preserved ejecion fraction (HFpEF)
- Sponsor
- Hieda Michinari
- Enrollment
- 38
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Persons who have given written consent of their own free will
- •2\) Age 40 years or older at the time of obtaining consent, regardless of gender
- •3\) Patients diagnosed with HFpEF (NYHA 1\-3\) with clinical symptoms of heart failure (fatigue, dyspnea, orthopnea, paroxysmal nocturnal dyspnea, leg edema) plus evidence of left ventricular ejection fraction over 50 percent, elevated left ventricular filling pressure (E/e' \>14\), and elevated plasma NT\-proBNP (\> 125 pg/mL).
Exclusion Criteria
- •1\) Patients with a history of cardiomyopathy (dilated cardiomyopathy or hypertrophic cardiomyopathy)
- •2\) Patients with a history of cardiac amyloidosis
- •3\) Patients with a history of cardiac sarcoidosis
- •4\) Patients with early onset of acute myocardial infarction or unstable angina pectoris
- •5\) Patients with constrictive pericarditis
- •6\) Patients with cardiogenic shock
- •7\) Patients with severe hepatic dysfunction (AST \> 10 times)
- •8\) Patients with moderate or severe valvular heart disease
- •9\) Patients with uncontrolled arrhythmia (atrial fibrillation, frequent extrasystoles, ventricular tachycardia, ventricular fibrillation)
- •10\) Patients with severe renal dysfunction (eGFR \< 30 ml/min/1\.73 m2\) and patients on dialysis
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
The effect of Empagliflozin on left ventricular ejection fraction in non-diabetic patients with acute anterior ST elevation Myocardial infarction treated with primary PCIAcute anterior ST elevation Myocardial infarction treated with primary PCI.ST elevation (STEMI) myocardial infarction of anterior wallI21.0IRCT20221227056950N1Mashhad University of Medical Sciences64
Active, not recruiting
Phase 1
Impact of empagliflozin on left ventricular functionstype 2 diabetesMedDRA version: 21.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2016-002225-10-ITAZIENDA OSPEDALIERO-UNIVERSITARIA PISANA75
Not yet recruiting
Phase 3
Effect of Empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes patients with heart failure with reduced ejection fractioHeart failure.Heart failure, unspecifiedI50.9IRCT20211219053450N1Ahvaz University of Medical Sciences112
Recruiting
Phase 4
Randomised trial of Empagliflozin and Left ventricular diastolic function in Acute Coronary Syndrome and Type 2 Diabetes (RELACS-T2D)ACTRN12621000355875Fiona Stanley Hospital80
Completed
Not Applicable
Impact of Dapagliflozin on Left ventricular hemodynamics and Exercise-induced Pulmonary hypertension evaluated by echocardiography in patients with type 2 diabetes; an open-label prospective randomized controlled trialJPRN-UMIN000023834The Japan Society for Patient Reported Outcome78